Enedra Therapeutics has secured venture financing and non-dilutive funding through UKRI’s Innovate UK Future Economy Investor Partnerships programme to support the development of next-generation precision therapies for advanced, genetically heterogeneous cancers. The financing round was supported by KU Leuven’s Centre for Drug Design and Discovery (CD3), o2h Ventures, and follow-on investor Cancer Research Horizons. Enedra […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!